HER2-targeted therapy combined with multidisciplinary management in advanced gallbladder cancer: a case report with 90-month survival
{{output}}
Biliary tract malignancies are highly lethal, with a 5-year overall survival (OS) rate of less than 10%. This report describes a patient with HER2-positive advanced gallbladder cancer who achieved an OS of 90 months through multidisciplinary interventions and ... ...
